サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439376

オーソバイオロジクス - 世界市場の考察、競合情勢、市場予測（2030年）

Orthobiologics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
オーソバイオロジクス - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のオーソバイオロジクスの市場規模は、2020年に53億3,000万米ドル、2030年までに68億4,000万米ドルに達し、2024年～2030年の予測期間にCAGRで4.44％の成長が見込まれます。オーソバイオロジクスに対する需要の高まりは主に、さまざまな骨変性疾患を発症しやすい老年人口の負担の増大、交通事故やスポーツ傷害などの外傷の患者の増加によるものです。さらに、主要メーカーによる研究開発や共同研究への投資の増加、さまざまなオーソバイオロジクス製品の承認の増加なども、世界のオーソバイオロジクス市場を強化すると予測されています。

オーソバイオロジクスの市場力学

オーソバイオロジクス市場は、変形性関節症、椎間板変性症などの骨変性疾患を発症しやすい老年人口の負担が増大しているため、現在速いペースで拡大しています。国連の「World Population Ageing 2019 highlights」によると、世界中で約7億300万人が65歳以上の高齢者でした。また、同レポートでは、2050年までに老年人口が15億人に増加すると推定しています。

さらに、世界保健機関（WHO）の2022年の統計によると、2020年に全世界で60歳以上の高齢者は約10億人に上ります。

さらに、Osteoarthritis Action Alliance（OAAA）（2020）で発表されたデータによると、2019年に、世界中で約2億4,200万人が、一般的な関節炎の1つである変形性関節症（OA）の症状や活動制限に苦しんでいます。また、2019年にOA患者の約43％が65歳以上、88％が45歳以上であることも報告されています。

加えて、近年のさまざまなオーソバイオロジクス製品の承認と発売もオーソバイオロジクス市場を急成長させると予測されています。例えば2019年2月28日、Medtronicは2018年8月に日本の医薬品医療機器総合機構（PMDA）によって承認された、脊椎と整形外科の手術向けの脱灰骨基質（DBM）骨移植製品、Grafton（TM）を日本で発売しました。

したがって、上記のすべての要因が予測期間に世界のオーソバイオロジクス市場を急成長させる見込みです。

しかし、オーソバイオロジクス治療に関連する高いコストと厳しい規制承認プロセスが、オーソバイオロジクス市場の抑制要因になる可能性があります。

COVID-19パンデミックの発生により、オーソバイオロジクス市場は成長が鈍化しました。これはパンデミックの間、選択的手術の数が遅れたためです。さらに、全国的なロックダウンによる診療所の一時的な閉鎖や、COVID-19パンデミック時に課されたロジスティクス制限による供給の混乱、病院のCOVID-19管理への注力へのシフトも、オーソバイオロジクス需要に影響を与えました。しかし、さまざまなワクチンの発売や集団予防接種の推進により、通常の業務が再開され、パンデミック後のオーソバイオロジクス市場の成長につながっています。

オーソバイオロジクス市場のセグメント分析

オーソバイオロジクス製品セグメントでは、関節内補充療法製品が今後数年間で大きな市場シェアを占めると予測されています。これは、世界の人々の変形性関節症の有病率が高いためです。Osteoarthritis Foundation International（OAFI Foundation）が2020年に発表したデータによると、世界では推定5億人が変形性関節症に罹患しており、変形性股関節症と変形性膝関節症がもっとも一般的です。関節内補充療法製品は、痛みを軽減する効果があり、症候性の変形性膝関節症の治療中に副作用が少ないことから、広く採用されており、オーソバイオロジクス市場のセグメント成長に寄与しています。

さらに、1回、3回、5回の注射を含む関節内補充療法製品の幅広い利用可能性も、このセグメントの成長を後押しすると予測されます。

当レポートでは、世界のオーソバイオロジクス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 オーソバイオロジクス市場レポートのイントロダクション

第2章 オーソバイオロジクス市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 オーソバイオロジクス市場の主な要因の分析

  • オーソバイオロジクス市場の促進要因
    • 交通事故や転倒などによる外傷の増加
    • 変形性骨疾患を発症しやすい高齢者の負担の増大
    • さまざまなオーソバイオロジクスの承認と発売の増加
    • オーソバイオロジクス開発に向けた企業による投資の増加
  • オーソバイオロジクス市場の抑制要因と課題
    • オルトバイオロジック製品と治療の高いコスト
    • 厳格な規制当局の承認
  • オーソバイオロジクス市場の機会
    • 主要企業による市場拡大に向けた戦略的な事業活動も成長機会をもたらす
    • 新興国におけるオーソバイオロジクス需要の高まり

第5章 オーソバイオロジクスのポーターのファイブフォース分析

第6章 オーソバイオロジクス市場に対するCOVID-19の影響分析

第7章 オーソバイオロジクス市場のレイアウト

  • 製品タイプ別
    • 関節内補充療法製品
    • 脱灰骨基質
    • 骨形成タンパク質
    • 合成人工骨
    • 骨移植片
    • その他
  • 用途別
    • 変形性関節症
    • 脊椎固定術
    • 軟部組織の損傷
    • 骨折の回復
    • 顎顔面、歯科用途
  • エンドユーザー別
    • 病院
    • 整形外科クリニック
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 オーソバイオロジクス：世界の企業シェア分析 - 主要3～5社

第9章 オーソバイオロジクスの企業と製品のプロファイル

  • Medtronic
  • Stryker
  • Collagen Matrix, Inc.
  • Arthrex, Inc.
  • Bioventus
  • Sanofi
  • Seikagaku Corporation
  • DePuy Synthes (Johnson & Johnson)
  • Globus Medical
  • Zimmer Biomet
  • NuVasive Inc.
  • SeaSpine
  • Baxter
  • Exactech, Inc.
  • RTI Surgical
  • Biomatlante
  • Fidia Farmaceutici S.p.A
  • LG Chem
  • TERUMO BCT, INC.
  • Anika Therapeutics, Inc.
  • Orthofix Medical Inc.
  • Kuros Biosciences
  • XTANT MEDICAL
  • APTISSEN
  • BONESUPPORT AB

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項と連絡先

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Orthobiologics Market
  • Table 3 Orthobiologics Market Analysis in Global (2018-2030)
  • Table 4 Orthobiologics Market Analysis in Global by Product Type (2018-2030)
  • Table 5 Orthobiologics Market Analysis in Global by Application (2018-2030)
  • Table 6 Orthobiologics Market Analysis in Global by End User (2018-2030)
  • Table 7 Orthobiologics Market Analysis in Global by Geography (2018-2030)
  • Table 8 Orthobiologics Market Analysis in North America (2018-2030)
  • Table 9 Orthobiologics Market Analysis in North America by Product Type (2018-2030)
  • Table 10 Orthobiologics Market Analysis in North America by Application (2018-2030)
  • Table 11 Orthobiologics Market Analysis in North America by End User (2018-2030)
  • Table 12 Orthobiologics Market Analysis in North America by Country (2018-2030)
  • Table 13 Orthobiologics Market Analysis in the US (2018-2030)
  • Table 14 Orthobiologics Market Analysis in Canada (2018-2030)
  • Table 15 Orthobiologics Market Analysis in Mexico (2018-2030)
  • Table 16 Orthobiologics Market Analysis in Europe (2018-2030)
  • Table 17 Orthobiologics Market Analysis in Europe by Product Type (2018-2030)
  • Table 18 Orthobiologics Market Analysis in Europe by Application (2018-2030)
  • Table 19 Orthobiologics Market Analysis in Europe by End User (2018-2030)
  • Table 20 Orthobiologics Market Analysis in Europe by Country (2018-2030)
  • Table 21 Orthobiologics Market Analysis in France (2018-2030)
  • Table 22 Orthobiologics Market Analysis in Germany (2018-2030)
  • Table 23 Orthobiologics Market Analysis in the UK (2018-2030)
  • Table 24 Orthobiologics Market Analysis in Italy (2018-2030)
  • Table 25 Orthobiologics Market Analysis in Spain (2018-2030)
  • Table 26 Orthobiologics Market Analysis in Russia (2018-2030)
  • Table 27 Orthobiologics Market Analysis in Rest of Europe (2018-2030)
  • Table 28 Orthobiologics Market Analysis in Asia-Pacific (2018-2030)
  • Table 29 Orthobiologics Market Analysis in Asia-Pacific by Product Type (2018-2030)
  • Table 30 Orthobiologics Market Analysis in Asia-Pacific by Application (2018-2030)
  • Table 31 Orthobiologics Market Analysis in Asia-Pacific by End User (2018-2030)
  • Table 32 Orthobiologics Market Analysis in Asia-Pacific by Country (2018-2030)
  • Table 33 Orthobiologics Market Analysis in China (2018-2030)
  • Table 34 Orthobiologics Market Analysis in Japan (2018-2030)
  • Table 35 Orthobiologics Market Analysis in India (2018-2030)
  • Table 36 Orthobiologics Market Analysis in Australia (2018-2030)
  • Table 37 Orthobiologics Market Analysis in South Korea (2018-2030)
  • Table 38 Orthobiologics Market Analysis in Rest of Asia-Pacific (2018-2030)
  • Table 39 Orthobiologics Market Analysis in Rest of World (2018-2030)
  • Table 40 Orthobiologics Market Analysis in Rest of World by Product Type (2018-2030)
  • Table 41 Orthobiologics Market Analysis in Rest of World by Application (2018-2030)
  • Table 42 Orthobiologics Market Analysis in Rest of World by End User (2018-2030)
  • Table 43 Orthobiologics Market Analysis in Rest of World by Country (2018-2030)
  • Table 44 Orthobiologics Market Analysis in the Middle East (2018-2030)
  • Table 45 Orthobiologics Market Analysis in Africa (2018-2030)
  • Table 46 Orthobiologics Market Analysis in South America (2018-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Orthobiologics Market
  • Figure 3 Orthobiologics Market Analysis in Global (2018-2030)
  • Figure 4 Orthobiologics Market Analysis in Global by Product Type (2018-2030)
  • Figure 5 Orthobiologics Market Analysis in Global by Application (2018-2030)
  • Figure 6 Orthobiologics Market Analysis in Global by End User (2018-2030)
  • Figure 7 Orthobiologics Market Analysis in Global by Geography (2018-2030)
  • Figure 8 Orthobiologics Market Analysis in North America (2018-2030)
  • Figure 9 Orthobiologics Market Analysis in North America by Product Type (2018-2030)
  • Figure 10 Orthobiologics Market Analysis in North America by Application (2018-2030)
  • Figure 11 Orthobiologics Market Analysis in North America by End User (2018-2030)
  • Figure 12 Orthobiologics Market Analysis in North America by Country (2018-2030)
  • Figure 13 Orthobiologics Market Analysis in the US (2018-2030)
  • Figure 14 Orthobiologics Market Analysis in Canada (2018-2030)
  • Figure 15 Orthobiologics Market Analysis in Mexico (2018-2030)
  • Figure 16 Orthobiologics Market Analysis in Europe (2018-2030)
  • Figure 17 Orthobiologics Market Analysis in Europe by Product Type (2018-2030)
  • Figure 18 Orthobiologics Market Analysis in Europe by Application (2018-2030)
  • Figure 19 Orthobiologics Market Analysis in Europe by End User (2018-2030)
  • Figure 20 Orthobiologics Market Analysis in Europe by Country (2018-2030)
  • Figure 21 Orthobiologics Market Analysis in France (2018-2030)
  • Figure 22 Orthobiologics Market Analysis in Germany (2018-2030)
  • Figure 23 Orthobiologics Market Analysis in the UK (2018-2030)
  • Figure 24 Orthobiologics Market Analysis in Italy (2018-2030)
  • Figure 25 Orthobiologics Market Analysis in Spain (2018-2030)
  • Figure 26 Orthobiologics Market Analysis in Russia (2018-2030)
  • Figure 27 Orthobiologics Market Analysis in Rest of Europe (2018-2030)
  • Figure 28 Orthobiologics Market Analysis in Asia-Pacific (2018-2030)
  • Figure 29 Orthobiologics Market Analysis in Asia-Pacific by Product Type (2018-2030)
  • Figure 30 Orthobiologics Market Analysis in Asia-Pacific by Application (2018-2030)
  • Figure 31 Orthobiologics Market Analysis in Asia-Pacific by End User (2018-2030)
  • Figure 32 Orthobiologics Market Analysis in Asia-Pacific by Country (2018-2030)
  • Figure 33 Orthobiologics Market Analysis in China (2018-2030)
  • Figure 34 Orthobiologics Market Analysis in Japan (2018-2030)
  • Figure 35 Orthobiologics Market Analysis in India (2018-2030)
  • Figure 36 Orthobiologics Market Analysis in Australia (2018-2030)
  • Figure 37 Orthobiologics Market Analysis in South Korea (2018-2030)
  • Figure 38 Orthobiologics Market Analysis in Rest of Asia-Pacific (2018-2030)
  • Figure 39 Orthobiologics Market Analysis in Rest of World (2018-2030)
  • Figure 40 Orthobiologics Market Analysis in Rest of World by Product Type (2018-2030)
  • Figure 41 Orthobiologics Market Analysis in Rest of World by Application (2018-2030)
  • Figure 42 Orthobiologics Market Analysis in Rest of World by End User (2018-2030)
  • Figure 43 Orthobiologics Market Analysis in Rest of World by Country (2018-2030)
  • Figure 44 Orthobiologics Market Analysis in the Middle East (2018-2030)
  • Figure 45 Orthobiologics Market Analysis in Africa (2018-2030)
  • Figure 46 Orthobiologics Market Analysis in South America (2018-2030)
  • Figure 47 Market Drivers
  • Figure 48 Market Barriers
  • Figure 49 Market Opportunities
  • Figure 50 PORTER's Five Force Analysis
目次
Product Code: DIMDCL0173

Orthobiologics Market By Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, Others), By Application (Osteoarthritis, Spinal Fusion, Reconstructive & Fracture Recovery, Soft-Tissue Injuries, Maxillofacial And Dental Applications), By End-User (Hospitals, Orthopaedic Clinics, And Others), by geography, is projected to expand at a significant CAGR till 2030 owing to the growing number of sports injuries & road accidents and increasing prevalence of bone degeneration diseases across the globe.

The global orthobiologics market was valued at USD 5.33 billion in 2020, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030, in order to reach USD 6.84 billion by 2030. The escalating demand for orthobiologics is predominantly attributed to the rising burden of the geriatric population who are susceptible to developing various bone degenerative disorders, increasing cases of traumatic injuries such as road crashes, sports injuries, and others. Moreover, growing investments in research & development and collaborations by key manufacturers, and the rise in various orthobiologic product approvals, among others are also expected to bolster the global orthobiologics market.

Orthobiologics Market Dynamics:

The market for orthobiologics is expanding at a faster pace at present owing to the growing burden of the geriatric population who are more susceptible to developing bone degenerative disorders such as osteoarthritis, degenerative disc disorders, and others. According to the United Nations World Population Ageing 2019 highlights, approximately 703 million people were aged 65 years and above across the globe. Also, the report estimated the old age population to rise to 1.5 billion by the year 2050.

In addition, as per the World Health Organization 2022 statistics, globally, there were about 1 billion persons aged 60 years or over in the year 2020.

Furthermore, as per the data published by the Osteoarthritis Action Alliance (OAAA), 2020, in the year 2019, about 242 million people worldwide suffer from symptomatic and activity limiting osteoarthritis (OA) which is one of the common types of arthritis. The data also mentioned that about 43% of people with OA are 65 or older and 88% of people with OA are 45 or older in 2019.

In addition, the recent approval and launch of various orthobiologic products are also anticipated to surge the market for orthobiologics. For instance, on February 28, 2019, Medtronic launched the Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopedic procedures in Japan which was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in August 2018.

Hence, all the above-mentioned factors are expected to spike the global orthobiologics market during the forecasted period.

However, high costs associated with orthobiologics treatment and stringent regulatory approval processes are likely to impede the market for orthobiologics.

Due to the outbreak of the COVID-19 pandemic, the market for orthobiologics witnessed slow growth. This is due to the delay in the number of elective procedures during the pandemic. Moreover, temporary shut down of clinics due to nationwide lockdown, disruption in supply because of logistical restrictions imposed at the time of COVID-19 wave, and hospitals shifting their focus towards COVID management also affected the orthobiologics demand. However, the launch of various vaccines and mass vaccination drives have resume normal operations further leading to the growth of the orthobiologics market during the post-pandemic.

Orthobiologics Market Segment Analysis:

Orthobiologics Market By Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, Others), By Application (Osteoarthritis, Spinal Fusion, Reconstructive & Fracture Recovery, Soft-Tissue Injuries, Maxillofacial And Dental Applications), By End-User (Hospitals, Orthopaedic Clinics, And Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the orthobiologics product segment, the viscosupplementation products are projected to hold a significant market share in the forthcoming years. This is because of the high prevalence of osteoarthritis among the world's population. According to the data published by the Osteoarthritis Foundation International (OAFI Foundation) in the year 2020, worldwide, an estimated 500 million people have osteoarthritis, hip and knee osteoarthritis being the most common. Extensive adoption of viscosupplementation products for their effectiveness in reducing pain, and fewer side effects while treating symptomatic knee osteoarthritis will contribute to the segmental growth of the orthobiologics market.

Moreover, the wide availability of viscosupplementation products including single, three, and five injections is also anticipated to boost the segmental growth.

Furthermore, approvals of various viscosupplementation devices in the market will also augment the market. For instance, in 2019, Fidia Farmaceutici S.p.A. received Food & Drug Administration (FDA) regulatory approval for TRILURON(TM), a single-use syringe, prefilled with sodium hyaluronate to provide relief to the pain associated with osteoarthritis for up to six months.

Also, rising manufacturers' initiatives to launch viscosupplementation products will surge the market. For instance, in May 2019, Lupin Limited and Aptissen S.A. entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute, and sell the current Aptissen products in Canada which includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis.

Thus, all the aforementioned factors are expected to drive the segmental growth of the orthobiologics market during the forecasted period.

North America is expected to dominate the Overall Orthobiologics Market:

Among all the regions, North America is expected to hold a major share in the overall orthobiologics market during the forecasted period. This domination is owing to the rising incidents of traumatic injuries due to falls, accidents, and others in the region. Moreover, increasing geriatric and obese people in the region, growing incidences of spinal disorders, and rising physician and patient awareness about newly introduced orthobiologic treatment procedures and technologies will further bolster the market for orthobiologics in the region.

For instance, in the US, an overall 48.3 million people suffered from traumatic injuries out of which motor-vehicle incidents totaled 4.5 million in the year 2019 as per the National Safety Council 2022 report.

Additionally, as per the 2022 statistics published by the Centers for Disease Control and Prevention, the prevalence of obesity in the US was 42.4% in the year between 2017 and 2018.

According to research, it has been concluded that obese people have reduced bone density which increases the risk of fractures.

Moreover, the presence of key players such as Arthrex Inc., Stryker Corporation, Medtronic, among others, and their strategic business activities for the development of new orthobiologics for the treatment of various bone-associated disorders will propel the orthobiologics market in the region. For instance, on November 11, 2020, Stryker acquired Wright Medical Group N.V. a leading medical device company focused on extremities and biologics to enhance its market position.

Also, in June 2019, Bioventus entered into a development collaboration agreement with MTF Biologics to co-develop the next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA).

Further, the Asia-Pacific region has the future potential growth for the Global orthobiologics market. This is due to the rising geriatric population in the region. According to the Organisation for Economic Cooperation and Development (OECD) 2022 statistics, across lower-middle and low-income Asia-Pacific countries, the share of the population aged 80 years and over is expected to triple between 2020 and 2050. The rising old age population is more susceptible to musculoskeletal disorders such as arthritis, osteoarthritis, and others. Thus, the expanding aging population could contribute to the orthobiologics market growth in the region. Furthermore, according to the Australian Institute of Health and Welfare 2020 report, from the years 2017 to 2018, one in eleven Australians have osteoarthritis making it approximately 2.2 million people in the nation. Thus, the rising prevalence of joint degeneration disorders will increase the demand for orthobiologics.

In addition, the presence of well-established market players such as Seikagaku Corporation, LG Chem., TERUMO BCT, INC., among others, the rising disposable income, improving healthcare facilities in the region are the factors expected to grow the market in the region.

Orthobiologics Market Key Players:

Some of the key market players operating in the Orthobiologics market include Medtronic, Stryker, Collagen Matrix, Inc., Arthrex, Inc., Bioventus, Sanofi, Seikagaku Corporation, DePuy Synthes (Johnson & Johnson), Globus Medical, Zimmer Biomet, NuVasive Inc., SeaSpine, Baxter, Exactech, Inc., RTI Surgical, Biomatlante, Fidia Farmaceutici S.p.A, LG Chem, TERUMO BCT, INC., Anika Therapeutics, Inc., Orthofix Medical Inc., Kuros Biosciences, XTANT MEDICAL, APTISSEN, BONESUPPORT AB, and others.

Recent Developmental Activities in the Orthobiologics Market:

On July 28, 2022, Orthofix Medical Inc., launched fiberFUSE strip, an advanced demineralized fiber bone graft solution containing cancellous bone in the US.

On July 13, 2022, RTI Surgical entered into a long-term strategic agreement with Exatech for the development and supply of biologic bone substitutes. As part of the agreement, RTI Surgical acquired Exactech's Optecure®, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities.

On August 24, 2020, Xtant Medical Holdings, Inc. launched its Matriform® Si, a silicated synthetic bone graft strip designed and cleared for spinal fusion procedures in the US.

Key Takeaways from the Orthobiologics Market Report Study

  • Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Orthobiologics market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the Global Orthobiologics Market.
  • Various opportunities available for the other competitor in the Orthobiologics Market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Orthobiologics market growth in the coming future?

Target Audience who can be benefited from the Orthobiologics Market Report Study

  • Orthobiologics providers
  • Research organizations and consulting companies
  • Orthobiologics-related organization, association, forum, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders in Orthobiologics
  • Various End-users who want to know more about the Orthobiologics Market and the latest technological developments in the Orthobiologics market.

Frequently Asked Questions for the Orthobiologics Market:

1. What are Orthobiologics?

Orthobiologics are substances used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are often made from substances that are naturally found in the body.

2. What is the market for Global Orthobiologics?

The global Orthobiologics Market was valued at USD 5.33 billion in 2020, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030 to reach USD 6.84 billion by 2030.

3. What are the drivers for Global Orthobiologics?

The major factors driving the demand for orthobiologics are the growing prevalence of joint degenerative disorders such as arthritis, osteoarthritis, and increasing cases of traumatic injuries due to sports injuries, road crashes, and others. Moreover, a rise in investments by key manufacturers for the R&D and commercialization of orthobiologics, and growing product approvals, among others are also projected to boost the global orthobiologics market.

4. What are the key players operating in Global Orthobiologics?

Some of the key market players operating in the Orthobiologics market include Medtronic, Stryker, Collagen Matrix, Inc., Arthrex, Inc., Bioventus, Sanofi, Seikagaku Corporation, DePuy Synthes (Johnson & Johnson), Globus Medical, Zimmer Biomet, NuVasive Inc., SeaSpine, Baxter, Exactech, Inc., RTI Surgical, Biomatlante, Fidia Farmaceutici S.p.A, LG Chem, TERUMO BCT, INC., Anika Therapeutics, Inc., Orthofix Medical Inc., Kuros Biosciences, XTANT MEDICAL, APTISSEN, BONESUPPORT AB, and others.

5. Which region has the highest share in the Orthobiologics market?

Among all the regions, North America is expected to hold a major share in the overall orthobiologics market during the forecasted period, 2024-2030. This domination is owing to the rising incidents of traumatic injuries due to falls, accidents, and others in the region. Moreover, increasing geriatric and obese people in the region, growing incidences of spinal disorders, and rising physician and patient awareness about newly introduced orthobiologic treatment procedures and technologies will further bolster the market for orthobiologics in the region.

Table of Contents

1.Orthobiologics Market Report Introduction

2.Orthobiologics Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Orthobiologics Market Key factors analysis

  • 4.1 Orthobiologics Market Drivers
    • 4.1.1 Growing cases of traumatic injuries due to traffic clashes, fall, and others
    • 4.1.2 The increasing burden of the old age population susceptible to develop degenerative bone diseases
    • 4.1.3 Rise in approval and launch of various orthobiologics
    • 4.1.4 Rise in investments by companies for the development of orthobiologics
  • 4.2 Orthobiologics Market Restraints and Challenges
    • 4.2.1 High cost of the orthobiologic products and treatment
    • 4.2.2 Stringent regulatory approvals
  • 4.3 Orthobiologics Market Opportunities
    • 4.3.1 Strategic business activities by key players for market expansion also provide growth opportunities
    • 4.3.2 Growing demand for orthobiologics in emerging countries

5. Orthobiologics Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Orthobiologics Market

7. Orthobiologics Market layout

  • 7.1 By Product Type
    • 7.1.1 Viscosupplementation Products
    • 7.1.2 Demineralized Bone Matrices
    • 7.1.3 Bone Morphogenic Protein
    • 7.1.4 Synthetic Bone Substitutes
    • 7.1.5 Bone grafts
    • 7.1.6 Others
  • 7.2 By Application
    • 7.2.1 Osteoarthritis
    • 7.2.2 Spinal Fusion
    • 7.2.3 Soft-tissue Injuries
    • 7.2.4 Fracture Recovery
    • 7.2.5 Maxillofacial and Dental Applications
  • 7.3 By End-user
    • 7.3.1 Hospitals
    • 7.3.2 Orthopaedic Clinics
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 North America Orthobiologics Market, by Product Type
      • 7.4.1.2 North America Orthobiologics Market, by Application
      • 7.4.1.3 North America Orthobiologics Market, by End User
      • 7.4.1.4 North America Orthobiologics Market, by Country
      • 7.4.1.4.1 United States
      • 7.4.1.4.2 Canada
      • 7.4.1.4.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 Europe Orthobiologics Market, by Product Type
      • 7.4.2.2 Europe Orthobiologics Market, by Application
      • 7.4.2.3 Europe Orthobiologics Market, by End User
      • 7.4.2.4 Europe Orthobiologics Market, by Country
      • 7.4.2.4.1 France
      • 7.4.2.4.2 Germany
      • 7.4.2.4.3 United Kingdom
      • 7.4.2.4.4 Italy
      • 7.4.2.4.5 Spain
      • 7.4.2.4.6 Russia
      • 7.4.2.4.7 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 Asia-Pacific Orthobiologics Market, by Product Type
      • 7.4.3.2 Asia-Pacific Orthobiologics Market, by Application
      • 7.4.3.3 Asia-Pacific Orthobiologics Market, by End User
      • 7.4.3.4 Asia-Pacific Orthobiologics Market, by Country
      • 7.4.3.4.1 China
      • 7.4.3.4.2 Japan
      • 7.4.3.4.3 India
      • 7.4.3.4.4 Australia
      • 7.4.3.4.5 South Korea
      • 7.4.3.4.6 Rest of Asia Pacific
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 RoW Orthobiologics Market, by Product Type
      • 7.4.4.2 RoW Orthobiologics Market, by Application
      • 7.4.4.3 RoW Orthobiologics Market, by End User
      • 7.4.4.4 RoW Orthobiologics Market, by Region
      • 7.4.4.1 Middle East
      • 7.4.4.2 Africa
      • 7.4.4.3 South America

8. Orthobiologics Global Company Share Analysis - Key 3-5 Companies

9. Orthobiologics Company and Product Profiles

  • 9.1 Medtronic
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Stryker
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Collagen Matrix, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Arthrex, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Bioventus
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Seikagaku Corporation
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 DePuy Synthes (Johnson & Johnson)
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Globus Medical
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Zimmer Biomet
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 NuVasive Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 SeaSpine
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Baxter
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 Exactech, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 RTI Surgical
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Biomatlante
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Fidia Farmaceutici S.p.A
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 LG Chem
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 TERUMO BCT, INC.
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 Anika Therapeutics, Inc.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy
  • 9.21 Orthofix Medical Inc.
    • 9.21.1. Company Overview
    • 9.21.2. Company Snapshot
    • 9.21.3. Financial Overview
    • 9.21.4 Product Listing
    • 9.21.5. Entropy
  • 9.22 Kuros Biosciences
    • 9.22.1. Company Overview
    • 9.22.2. Company Snapshot
    • 9.22.3. Financial Overview
    • 9.22.4 Product Listing
    • 9.22.5. Entropy
  • 9.23 XTANT MEDICAL
    • 9.23.1. Company Overview
    • 9.23.2. Company Snapshot
    • 9.23.3. Financial Overview
    • 9.23.4 Product Listing
    • 9.23.5. Entropy
  • 9.24 APTISSEN
    • 9.24.1. Company Overview
    • 9.24.2. Company Snapshot
    • 9.24.3. Financial Overview
    • 9.24.4 Product Listing
    • 9.24.5. Entropy
  • 9.25 BONESUPPORT AB
    • 9.25.1. Company Overview
    • 9.25.2. Company Snapshot
    • 9.25.3. Financial Overview
    • 9.25.4 Product Listing
    • 9.25.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us